espanolEl carcinoma inflamatorio de mama es una entidad infrecuente, pero representa una presentacion agresiva del cancer de mama. A pesar de los avances en cancer de mama, el pronostico del carcinoma inflamatorio de mama sigue siendo pobre. Los estudios son retrospectivos, con muestras pequenas o extrapolaciones del carcinoma de mama no inflamatorio. No obstante, hay suficiente evidencia para sugerir que difiere del no inflamatorio. El manejo optimo se basa en un tratamiento multimodal, que consiste en quimioterapia neoadyuvante, cirugia y radioterapia. El tratamiento sistemico se basa en esquemas de quimioterapia basados en antraciclinas y taxanos. En enfermedad HER2 positiva se debe asociar trastuzumab, resultando en un incremento de respuesta completa patologica. La mastectomia con linfadenectomia continua siendo el tratamiento estandar, independientemente de la respuesta a la quimioterapia neoadyuvante. La investigacion traslacional puede ayudar a aclarar la etiologia y la biologia de esta entidad agresiva. EnglishInflammatory breast cancer is rare but represents the most aggressive presentation of breast cancer. Despite the progress in breast cancer treatment, the prognosis remains poor. Available data were from retrospective studies, small prospective studies, and extrapolation from prospective trials evaluating women with non-inflammatory tumours. But, there is sufficient evidence to suggest that inflammatory breast cancer differs from non-inflammatory breast cancer. The key approach for the optimal management is a multimodality treatment that includes neoadjuvant systemic treatment,surgery and radiotherapy. Neoadjuvant chemotherapy based on anthracycline and taxanes is the standard of care. For HER2-positive disease the addition of anti-HER2 agents to systemic therapy increases pathologic complete response rate. Mastectomy with axillary dissection followed by radiotherapy remains the standard locoregional treatment regardlessof the response to preoperative therapy. Translational research efforts should be directed to clarify the etiology and biology of this aggressive entity.